Stock Events

Stock Events

Soleno Therapeutics 

€44.88
0
+€0+0% Friday 06:05

Statistics

Day High
44.88
Day Low
44.88
52W High
74.5
52W Low
26.48
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q4 2025
Next
0.58
0.61
0.65
0.68
Expected EPS
0.5824472
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 6XC.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.49B
BioMarin Pharmaceutical develops and commercializes innovative therapies for rare genetic diseases, directly competing with Soleno's therapeutic areas.
Sarepta Therapeutics
SRPT
Mkt Cap2.22B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for rare diseases, competing in the same therapeutic area as Soleno.
PTC Therapeutics
PTCT
Mkt Cap5.7B
PTC Therapeutics operates in the field of genetic disorders, including rare diseases, making it a direct competitor to Soleno Therapeutics.
Ultragenyx Pharmaceutical
RARE
Mkt Cap2.21B
Ultragenyx Pharmaceutical targets rare and ultra-rare diseases with its advanced therapies, competing in the same niche as Soleno.
Ionis Pharmaceuticals
IONS
Mkt Cap12.42B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, including treatments for rare diseases, overlapping with Soleno's focus.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.72B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, targeting genetic and rare diseases, which puts it in competition with Soleno.
CRISPR Therapeutics
CRSP
Mkt Cap4.92B
CRISPR Therapeutics is involved in gene editing technology, which has applications in treating rare diseases, potentially competing with Soleno's therapeutic approach.

About

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Show more...
CEO
Dr. Anish Bhatnagar M.D.
Employees
115
Country
United States
ISIN
US8342033094

Listings

STU
DE
6XC.STU
MU
DE
6XC.MU
XNAS
US
SLNO
F
DE
6XC.F

0 Comments

Share your thoughts

FAQ

What is Soleno Therapeutics stock price today?▼
The current price of 6XC.MU is €44.88 EUR — it has increased by +0% in the past 24 hours. Watch Soleno Therapeutics stock price performance more closely on the chart.
What is Soleno Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Soleno Therapeutics stocks are traded under the ticker 6XC.MU.
When is the next Soleno Therapeutics earnings date?▼
Soleno Therapeutics is going to release the next earnings report on May 12, 2026.
What were Soleno Therapeutics earnings last quarter?▼
6XC.MU earnings for the last quarter are 0.68 EUR per share, whereas the estimation was 0.6 EUR resulting in a +12.55% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Soleno Therapeutics have?▼
As of April 13, 2026, the company has 115 employees.
In which sector is Soleno Therapeutics located?▼
Soleno Therapeutics operates in the Health & Wellness sector.
When did Soleno Therapeutics complete a stock split?▼
Soleno Therapeutics has not had any recent stock splits.
Where is Soleno Therapeutics headquartered?▼
Soleno Therapeutics is headquartered in Redwood City, United States.